EXEL - Exelixis, Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 24.27 |
| Open | 24.18 |
| Bid | 0.00 x 900 |
| Ask | 23.99 x 1400 |
| Day's Range | 23.14 - 24.46 |
| 52 Week Range | 13.67 - 27.80 |
| Volume | 2,480,676 |
| Avg. Volume | 3,959,885 |
| Market Cap | 7.105B |
| Beta (5Y Monthly) | 1.61 |
| PE Ratio (TTM) | 11.85 |
| EPS (TTM) | 1.96 |
| Earnings Date | Jul 29, 2020 - Aug 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.85 |
Fair Value
Related Research
- Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in June:
- Thomson Reuters StreetEvents
Edited Transcript of EXEL earnings conference call or presentation 5-May-20 9:00pm GMT
Q1 2020 Exelixis Inc Earnings Call
- Simply Wall St.
Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 49% Undervaluation?
Today we will run through one way of estimating the intrinsic value of Exelixis, Inc. (NASDAQ:EXEL) by taking the...
- Investopedia
3 Charts That Suggest Biotech Stocks Are Headed Higher
Breakouts beyond key levels of resistance suggest that the bulls are in control of the momentum in the biotech sector.
- Business Wire
Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The data from three expansion cohorts of the COSMIC-021 trial will be presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20). Results from the non-small cell lung cancer (NSCLC) and the metastatic castration-resistant prostate cancer (CRPC) cohorts will be presented as posters, and results from the urothelial carcinoma (UC) cohort will be presented as a poster discussion; all three presentations will be available on demand for ASCO20 registrants beginning Friday, May 29 at 8:00 a.m. ET.
- Motley Fool
Better Buy: bluebird bio vs. Exelixis
Exelixis (NASDAQ: EXEL) and bluebird bio (NASDAQ: BLUE) are two biotech companies that have been moving in opposite directions on the stock market this year. While Exelixis has provided healthy gains -- its stock is up by 52.1% year to date -- Bluebird's shares have slid by 35.2% since the beginning of the year. With this backdrop in mind, it might be tempting to pick Exelixis as the better stock to buy.
- Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in fireside chats at the following virtual investor conferences in May:
- Zacks
Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates
Exelixis (EXEL) beats on earnings and sales in the first quarter and maintains annual outlook amid coronavirus.
- Motley Fool
Exelixis Inc (EXEL) Q1 2020 Earnings Call Transcript
EXEL earnings call for the period ending March 31, 2020.
- Zacks
Exelixis (EXEL) Q1 Earnings and Revenues Beat Estimates
Exelixis (EXEL) delivered earnings and revenue surprises of 15.38% and 6.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
- ACCESSWIRE
Exelixis, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 5, 2020 / Exelixis, Inc. (NASDAQ:EXEL) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 5, 2020 at 5:00 PM Eastern Time. ...
- TheStreet.com
Exelixis Charts Are Pointed Higher, Look to Buy a Dip
Exelixis : "I've liked this one all the way," said Jim Cramer to a caller during the 'Lightning Round' of Mad Money Thursday night. Exelixis is a genomics-based drug discovery company and the producer of Cometriq, a treatment approved for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. In this daily bar chart of EXEL, below, we can see that prices made a huge upside price gap or void last month.
- Simply Wall St.
How Does Exelixis's (NASDAQ:EXEL) P/E Compare To Its Industry, After Its Big Share Price Gain?
Exelixis (NASDAQ:EXEL) shares have had a really impressive month, gaining 60%, after some slippage. And the full year...
- Business Wire
Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020
Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2020 financial results will be released on Tuesday, May 5, 2020 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
- Investor's Business Daily
Exelixis Stock Strength Jumps On Positive Cancer Treatment Results
Exelixis shares was roughly unchanged Tuesday, holding gains after a massive 21% jump on Monday amid positive test results for a new cancer medicine. The South San Francisco-based company saw a positive improvement to its IBDÂ Relative Strength (RS) Rating on Tuesday, with an upgrade from 84 to 95. The rating upgrade came after Exelixis and partner Bristol-Myers Squibb on Monday announced positive results in a Phase 3 test of a kidney cancer treatment.
- American City Business Journals
How this East Bay biotech pushed past the 'negativity' with a big boost to its kidney cancer drug
The company's stock soared Monday on results from a late-stage clinical trial pairing with a major cancer immunotherapy.
- Investor's Business Daily
This Biotech Stock Just Blew Into A Profit-Taking Zone — Here's Why
Exelixis stock rocketed Monday after the biotech company's Bristol Myers Squibb-partnered kidney cancer treatment succeeded in a Phase 3 test. The duo tested Cabometyx plus Opdivo.
- TheStreet.com
Kidney Cancer Drug From Bristol-Myers and Exelixis Meets Key Phase III Endpoint
A kidney-cancer drug candidate combining treatments from Bristol-Myers and Exelixis met its primary endpoint of progression-free survival, the companies said. Exelixis shares jumped on the report.
- MarketWatch
Exelixis, Bristol-Myers stocks get a boost from upbeat trial results of a Kidney cancer treatment
Shares of Exelixis Inc. shot up 8.1%, while Bristil-Myers Squibb Co.'s stock slipped 0.3% in premarket trading Monday, after the companies said a phase 3 study of a treatment for kidney cancer met its primary and secondary endpoints. "The results from the pivotal CheckMate -9ER trial clearly demonstrate the combination of cabozantinib plus nivolumab provides a clinically meaningful benefit in the key efficacy measures of progression-free survival and overall survival for previously untreated kidney cancer patients," said Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute. The stocks' moves come in the face of a broad-market selloff, with futures for the S&P 500 falling 1.5%.
- Business Wire
Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma
BMS and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo in Combination with CABOMETYX...
- Reuters
CORRECTED-Bristol Myers says Opdivo performs well in kidney, lung cancer trials
Bristol Myers Squibb Co said on Monday that its blockbuster cancer immunotherapy Opdivo performed well in two separate late-stage trials, prolonging survival in previously untreated patients with kidney cancer and lung cancer. Opdivo is one of Bristol’s top-selling drugs, but sales of the drug have slowed in recent years as it has been eclipsed by Merck & Co’s rival drug Keytruda. New Jersey-based Bristol said Opdivo used in combination with Exelixis Inc's drug Cabometyx significantly improved progression-free survival - a measure of the drugs' ability to delay the disease worsening - in patients with advanced kidney cancer.
- Business Wire
Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will participate in a fireside chat as part of the 19th Annual Needham Healthcare Conference on Wednesday, April 15, 2020 at 11:20 AM EDT / 8:20 AM PDT. Due to the ongoing COVID-19 pandemic, the conference has been converted to a virtual event.
- Insider Monkey
Were These Hedge Funds Right About Selling Exelixis, Inc. (EXEL)?
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- Business Wire
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma (RCC).
